

Quarterly HOTLINE: Effective February 19, 2019

2013284 PD-L1 22C3 IHC with Tumor Proportion Score (TPS) Interpretation, pembrolizumab (KEYTRUDA) 22C3 IP

HOTLINE NOTE: Name change only.